The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information:

Study Name on (link is external)
A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler
Study DrugBI 1265162
Type of Study DrugENaC inhibitor 
Study TitleA randomised, double-blind, placebo-controlled and parallel group trial to evaluate efficacy and safety of twice daily inhaled doses of BI 1265162 delivered by Respimat® inhaler as add-on therapy to standard of care over 4 weeks in patients with cystic fibrosis
Study Phase2
Study SponsorBoehringer Ingelheim

Link on (link is external)

Participating ECFS-CTN sitesPlease contact for most recent sitelist
Age12 years and older